# Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

> **NCT01339988** · PHASE4 · UNKNOWN · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Acute Leukemias
- Chronic Leukemias
- Myelodysplastic Syndrome
- Juvenile Myelomonocytic Leukemia

## Interventions

- **DRUG:** Busulfan/Cyclophosphamide

## Key facts

- **NCT ID:** NCT01339988
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2014-06
- **Final completion:** 2019-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2011-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339988, "Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01339988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*